Plasma is a key
raw material of the blood product industry. In August 2011, China shut down 16
plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume
of the year. However, due to the implementation of favorable policies, widening
gap between supply and demand, rising product prices and other factors, more
than 150 plasma stations in China produced about 3,600 tons of plasma in 2012,
up 14.2% year on year.
To
Read The Complete Report with TOC :-
From 2012 to
mid-2013, new plasma stations of some Chinese enterprises have started plasma
collection or obtained plasma collection permits, such as Yuechi plasma station
of Jiangxi Boya Bio-Pharmaceutical, Changyuan plasma station of Hualan Bio, and
Caoxian plasma station of China Biologic Products. It’s expected that China’s
plasma supply tension will be further eased after 2013.
According to the
lot release statistics of National Institutes for Food and Drug Control, in the
first ten months of 2012, China’s total lot release volume of blood products
was about 36.13 million bottles, an increase of 7.1% compared with the full
year of 2011. In addition, except human coagulation factor VIII with a
decreased lot release volume, other products saw growing release volume. In
particular, human immunoglobulin, tetanus immunoglobulin, human fibrinogen,
imported human serum albumin witnessed higher growth rates of 321%, 95%, 79%,
45% respectively in the first ten months of 2012.
To
Read The Complete Report with TOC :-
However, Chinese
blood product enterprises have weak R&D capability, low plasma utilization
and fewer product varieties. The domestic market is still dominated by
technically undemanding human serum albumin and human immunoglobulin (ph4) for
intravenous injection, which accounted for more than 60% of the lot release
volume in 2012.
In order to ease
the domestic shortage of blood products, China has allowed the import of human
serum albumin and recombinant coagulation factor VIII in recent years. Human
serum albumin imports have grown rapidly due to low prices. The lot release
volume was 8.51 million bottles in the first ten months of 2012, occupying
47.5% of the lot release volume of such products (43.3% in 2011); Behring,
Baxter, Instituto Grifols and Octapharma were top four companies by lot release
volume. However, due to high prices and national policy restrictions, the
import of recombinant coagulation factor VIII is very small, only Bayer and
Baxter products were allowed to be imported as of the end of 2012.
China Blood
Product Industry Report, 2012-2015 covers the followings:
- Plasma volume, plasma station distribution, market size and supply & demand of China blood product industry;
- Competition pattern, policy environment and import & export of China blood product industry;
- Market supply & demand and competition pattern of eight categories of blood products including human serum albumin, human immunoglobulin (ph4) for intravenous injection, coagulation factors in China;
- Development, operation, plasma stations and lot release volume of 12 local blood product producers in China.
To Buy a Copy Of This Report:-
As of the end of
2012, there were about 30 enterprises passing GMP certification and in normal
operation, among them, only Hualan Bio, Tiantan Biological Products (including
Chengdu Ronsen), Shanghai RAAS, Yuanda Shuyang Pharmaceutical, China Biologic
Products have an annual plasma volume of over 300 tons. In 2012, the five
enterprises accounted for 56.1% of China’s total plasma volume, and about 30%
of China’s blood product market revenue.
Guangdong
Shuanglin Bio-pharmacy, the sixth place holder, had nine plasma stations (three
under construction) in 2012, with a plasma volume of about 247 tons and blood product
revenue of RMB 431 million. The company has held the largest lot release volume
of rabies immunoglobulin in recent years. Jiangxi Boya, though occupying a
small market share (1.8% in 2012 by sales), has seven plasma stations, with
output and sales volume expected to be further enhanced in the future.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment